

Please substitute the paragraph at page 9, lines 12-20 with the following replacement paragraph. A marked-up copy of this paragraph, showing the changes made thereto, is attached.

Examples of the antibiotic include minocycline, tetracycline, piperacillin sodium, sultamicillin tosylate, amoxicilline, ampicillin, bacampicillin, aspoxicilin, cefdinir, flomoxef sodium, cefotiam, cefcapene pivoxil, cefaclor, cefteteram pivoxil, cephalosin sodium, cefradine, clarithromycin, clindamycin, erythromycin, levofloxacin, tosufloxacin tosylate, ofloxacin, ciprofloxacin, arbekacin, isepamicin, dibekacin, amikacin, gentamicin, vancomycin, fosfomycin, derivatives thereof, and the like.

IN THE CLAIMS:

Please amend Claims 1-16 and 19-25 to read as follows. A marked-up copy of these claims, showing the changes made thereto, is attached.

1. (Amended) A method of preparing a drug encapsulated in liposomes, which comprises selecting a drug and encapsulating said drug using at least two lipid bilayers of the liposomes.

2. (Amended) A method of preparing a drug encapsulated in liposomes, which comprises selecting a drug and encapsulating said drug using lipid having a phase transition temperature higher than *in vivo* temperature as lipid constituting the liposomes.

3. (Amended) A method of preparing a drug encapsulated in liposomes, which comprises selecting a drug and encapsulating said drug satisfying at least two requirements selected from the group consisting of: using at least two lipid bilayers of the liposomes, controlling the average particle size of the liposomes to 120 nm or more, and using lipid having a phase transition temperature higher than *in vivo* temperature as lipid constituting the liposomes.

4. (Amended) The method according to claim 2 or 3, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

5. (Amended) The method according to claim 2 or 3, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

6. (Amended) The method according to claim 3, which comprises using at least two lipid bilayers of the liposomes, and controlling the average particle size of the liposomes to 120 nm or more.

7. (Amended) The method according to claim 3 or 6, wherein the liposomes have an average particle size of 120 to 500 nm.

8. (Amended) The method according to any one of claims 1 to 3 or 6, wherein

the biological component is a blood component.

9. (Amended) The method according to claim 8, wherein the drug encapsulated is an indolocarbazole derivative.

10. (Amended) The method according to claim 8, wherein the drug encapsulated is an antitumor agent.

11. (Amended) The method according to claim 8, wherein the drug encapsulated is an antibiotic.

12. (Amended) The method according to claim 8, wherein the drug encapsulated is a pharmaceutically active substance.

13. (Amended) A liposome preparation comprising encapsulated drug, at least two lipid bilayers, and having an average particle size of 120 nm or more.

14. (Amended) A liposome preparation comprising encapsulated drug, at least two lipid bilayers wherein the lipid constituting the liposomes has a phase transition temperature higher than *in vivo* temperature.

15. (Amended) A liposome preparation comprising an encapsulated drug, and

wherein the liposomes have an average particle size of 120 nm or more, and the lipid constituting the liposomes has a phase transition temperature higher than *in vivo* temperature.

Q3 could
16. (Amended) A liposome preparation comprising an encapsulated drug, wherein said liposome satisfies at least two requirements selected from the group consisting of: the number of lipid bilayers of the liposomes is at least two, the liposomes have an average particle size of 120 nm or more, and lipid constituting the liposomes has a phase transition temperature higher than *in vivo* temperature.

Q4
19. (Amended) The liposome preparation according to any one of claims 14 to 16, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

20. (Amended) The liposome preparation according to any one of claims 14 to 16, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine, polyethylene glycol-modified phospholipid, and cholesterol.

21. (Amended) The liposome preparation according to any one of claims 13, 15 or 16, wherein the liposomes have an average particle size of 120 to 500 nm.

22. (Amended) The liposome preparation according to claim 21, wherein the